Suppr超能文献

在德国引入A群脑膜炎球菌结合疫苗(MenACWY)接种策略的公共卫生影响和成本效益

Public health impact and cost-effectiveness of introducing MenACWY vaccination strategies in Germany.

作者信息

Schley Katharina, Janßen Sabrina, Sullivan Shannon M, Tichy Eszter, Findlow Jamie

机构信息

Pfizer Pharma GmbH, Friedrichstr. 110, 10117, Berlin, Germany.

Evidera/PPD, 27-35, rue Victor Hugo, Ivry-sur-Seine CEDEX, 94853, France.

出版信息

BMC Public Health. 2025 May 5;25(1):1653. doi: 10.1186/s12889-025-21491-3.

Abstract

BACKGROUND

The invasive meningococcal disease (IMD) routine immunization recommendation in Germany is a meningococcal serogroup C (MenC) conjugate vaccine for toddlers aged 12 months with a catch-up for unimmunized up to 17 years. However, there are no recommendations for routine meningococcal serogroups A, C, W, Y (MenACWY) vaccination or for adolescent vaccinations; this differs from other European countries. This analysis aimed to understand the benefits of implementing adolescent MenACWY vaccination in Germany.

METHODS

A static population-cohort model evaluating IMD burden and related health outcomes (e.g., cases, cases with long-term sequelae, deaths) was developed to compare any two meningococcal vaccination strategies. We compared hypothetical vaccination strategies that included different approaches to adolescent vaccination in Germany, such as vaccinating at 13-year olds versus 16-year olds and vaccinating with MenC versus MenACWY. Additional strategies considered the benefit that could be provided by switching the current MenC vaccine recommendation in toddlers to MenACWY.

RESULTS

All strategies that included MenACWY vaccine were effective in decreasing the number of cases, preventing mortality and offered good value for money. The greatest benefit was observed in individuals vaccinated with MenACWY at 12 months and 16 years of age (2,978 IMD cases averted; 563 IMD deaths prevented). Compared with the current strategy of MenC vaccination at 12 months of age, two-dose strategies that included MenACWY reported incremental cost-effectiveness ratios <€13,205 per quality-adjusted life year. Adolescent strategies of MenC or MenACWY vaccine at 16 years old (with no vaccination at 12 months) dominated current vaccination strategies. Adolescent vaccination at 16 years old versus 13 years old offered slightly better value for money.

CONCLUSIONS

With recent increases in IMD cases and outbreaks occurring globally following the COVID-19 pandemic, there is a greater urgency to proactively implement a MenACWY vaccine recommendation to protect adolescents in Germany. This recommendation would provide direct protection to a group at increased risk and offer indirect protection to other population groups. Implementation of a school-based immunization program could increase vaccine uptake and overcome hurdles in adolescent vaccination.

摘要

背景

德国侵袭性脑膜炎球菌病(IMD)的常规免疫接种建议是为12个月大的幼儿接种C群脑膜炎球菌结合疫苗,并为17岁以下未接种疫苗的儿童进行补种。然而,对于A、C、W、Y群脑膜炎球菌(MenACWY)的常规疫苗接种或青少年疫苗接种尚无建议;这与其他欧洲国家不同。本分析旨在了解在德国实施青少年MenACWY疫苗接种的益处。

方法

建立了一个静态人群队列模型,评估IMD负担及相关健康结局(如病例数、有长期后遗症的病例数、死亡数),以比较任意两种脑膜炎球菌疫苗接种策略。我们比较了假设的疫苗接种策略,这些策略包括德国青少年疫苗接种的不同方法,例如在13岁或16岁时接种,以及接种C群脑膜炎球菌疫苗(MenC)与MenACWY疫苗。其他策略考虑了将目前针对幼儿的MenC疫苗接种建议改为MenACWY疫苗接种可能带来的益处。

结果

所有包含MenACWY疫苗的策略在减少病例数、预防死亡方面均有效,且性价比高。在12个月和16岁时接种MenACWY疫苗的个体获益最大(避免了2978例IMD病例;预防了563例IMD死亡)。与目前12个月龄接种MenC疫苗的策略相比,包含MenACWY疫苗的两剂次策略每质量调整生命年的增量成本效益比<13,205欧元。16岁时接种MenC或MenACWY疫苗的青少年策略(12个月时未接种)优于目前的疫苗接种策略。16岁接种疫苗相比13岁接种疫苗性价比略高。

结论

随着COVID-19大流行后全球IMD病例数近期增加且出现疫情,德国迫切需要积极实施MenACWY疫苗接种建议以保护青少年。该建议将为风险增加的群体提供直接保护,并为其他人群提供间接保护。实施基于学校的免疫计划可提高疫苗接种率并克服青少年疫苗接种的障碍。

相似文献

1
Public health impact and cost-effectiveness of introducing MenACWY vaccination strategies in Germany.
BMC Public Health. 2025 May 5;25(1):1653. doi: 10.1186/s12889-025-21491-3.
4
Public Health Impact of Introducing a Pentavalent Vaccine Against Invasive Meningococcal Disease in the United States.
Pharmacoeconomics. 2025 Mar;43(3):311-329. doi: 10.1007/s40273-024-01439-y. Epub 2024 Nov 25.
5
Cost-effectiveness of meningococcal polysaccharide serogroups A, C, W-135 and Y conjugate vaccine in Australian adolescents.
Vaccine. 2019 Aug 14;37(35):5009-5015. doi: 10.1016/j.vaccine.2019.07.008. Epub 2019 Jul 10.
6
Modelling the Public Health Impact of MenACWY and MenC Adolescent Vaccination Strategies in Germany.
Infect Dis Ther. 2024 Apr;13(4):907-920. doi: 10.1007/s40121-024-00958-7. Epub 2024 Apr 4.
7
Meningococcal serogroup A, C, W₁₃₅ and Y conjugated vaccine: a cost-effectiveness analysis in the Netherlands.
PLoS One. 2013 May 31;8(5):e65036. doi: 10.1371/journal.pone.0065036. Print 2013.
8
Evolving strategies for meningococcal vaccination in Europe: Overview and key determinants for current and future considerations.
Pathog Glob Health. 2022 Mar;116(2):85-98. doi: 10.1080/20477724.2021.1972663. Epub 2021 Sep 27.

本文引用的文献

1
Epidemiology of invasive meningococcal disease worldwide from 2010-2019: a literature review.
Epidemiol Infect. 2023 Mar 6;151:e57. doi: 10.1017/S0950268823000328.
4
A policy review of the introduction of the MenACWY vaccine in toddlers across multiple countries.
Expert Rev Vaccines. 2022 Nov;21(11):1637-1646. doi: 10.1080/14760584.2022.2128771. Epub 2022 Oct 12.
6
Impact of COVID-19 Containment Strategies and Meningococcal Conjugate ACWY Vaccination on Meningococcal Carriage in Adolescents.
Pediatr Infect Dis J. 2022 Nov 1;41(11):e468-e474. doi: 10.1097/INF.0000000000003660. Epub 2022 Jul 27.
7
Increased Incidence of Invasive Pneumococcal Disease among Children after COVID-19 Pandemic, England.
Emerg Infect Dis. 2022 Aug;28(8):1669-1672. doi: 10.3201/eid2808.220304.
8
Impact of meningococcal ACWY conjugate vaccines on pharyngeal carriage in adolescents: evidence for herd protection from the UK MenACWY programme.
Clin Microbiol Infect. 2022 Dec;28(12):1649.e1-1649.e8. doi: 10.1016/j.cmi.2022.07.004. Epub 2022 Jul 13.
9
The Impact of Broader Value Elements on Cost-Effectiveness Analysis: Two Case Studies.
Value Health. 2022 Aug;25(8):1336-1343. doi: 10.1016/j.jval.2022.01.025. Epub 2022 Mar 18.
10
Epidemiology and economic burden of meningococcal disease in Germany: A systematic review.
Vaccine. 2022 Mar 18;40(13):1932-1947. doi: 10.1016/j.vaccine.2022.02.043. Epub 2022 Feb 25.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验